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Cytomegalovirus Serology and Replication Remain
Associated With Solid Organ Graft Rejection and Graft
Loss in the Era of Prophylactic Treatment
Martin Stern,1,11 Hans Hirsch,2,3 Alexia Cusini,4 Christian van Delden,5 Oriol Manuel,6
Pascal Meylan,7 Katia Boggian,8 Nicolas J. Mueller,9 and Michael Dickenmann,10
and on behalf of all members of the Swiss Transplant Cohort Study
Background. Cytomegalovirus (CMV) replication has been associated with more risk for solid organ graft rejection.
We wondered whether this association still holds when patients at risk receive prophylactic treatment for CMV.
Methods. We correlated CMV infection, biopsy-proven graft rejection, and graft loss in 1,414 patients receiving heart
(n=97), kidney (n=917), liver (n=237), or lung (n=163) allografts reported to the Swiss Transplant Cohort Study.
Results. Recipients of all organs were at an increased risk for biopsy-proven graft rejection within 4 weeks after de-
tection of CMV replication (hazard ratio [HR] after heart transplantation, 2.60; 95% confidence interval [CI],
1.34Y4.94, PG0.001; HR after kidney transplantation, 1.58; 95% CI, 1.16Y2.16, P=0.02; HR after liver transplantation,
2.21; 95% CI, 1.53Y3.17, PG0.001; HR after lung transplantation, 5.83; 95% CI, 3.12Y10.9, PG0.001. Relative hazards
were comparable in patients with asymptomatic or symptomatic CMV infection. The CMV donor or recipient se-
rological constellation also predicted the incidence of graft rejection after liver and lung transplantation, with sig-
nificantly higher rates of rejection in transplants in which donor or recipient were CMV seropositive (non-Dj/Rj),
compared with Dj transplant or Rj transplant (HR, 3.05; P=0.002 for liver and HR, 2.42; P=0.01 for lung trans-
plants). Finally, graft loss occurred more frequently in non-Dj or non-Rj compared with Dj transplant or Rj
transplant in all organs analyzed. Valganciclovir prophylactic treatment seemed to delay, but not prevent, graft loss in
non-Dj or non-Rj transplants.
Conclusion. Cytomegalovirus replication and donor or recipient seroconstellation remains associated with graft
rejection and graft loss in the era of prophylactic CMV treatment.
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(Transplantation 2014;98: 1013Y1018)
Cytomegalovirus (CMV) infection is among the mostfrequent complications after solid organ transplanta-
tion (SOT) (1). De novo infection can occur if passenger
leukocytes contained in the graft of a seropositive donor
mediate primary infection in a seronegative patient. Sec-
ondary reactivation in seropositive recipients is also fre-
quent and is caused by pharmacologically compromised
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T-cell immunity in patients with latent infection. Intensifica-
tion of immunosuppression to prevent or treat graft rejection
is therefore an established risk factor for CMV replication (2).
Several reports have suggested that the relationship
between CMV and rejection is complex: not only can re-
jection (and its treatment) act as a risk factor for CMV re-
plication but CMV infection can also trigger graft rejection.
In a mouse heart transplant model, latent murine CMV
infection was able to induce graft rejection (3). Similarly, an
early single-center study found an almost sixfold increase in
the risk of graft rejection in the month after CMV disease
after kidney transplantation (4). In several studies, CMV dis-
ease was associated with an increase in graft loss after kidney
or combined kidney and pancreas transplantation (5Y7).
Comparable data exist for patients receiving lung (8), heart
(9), or liver (10) allografts. Pathophysiologically, the systemic
inflammation induced by CMV replication might alter the
fragile state of graft tolerance in the transplanted patient and
trigger graft rejection (11). Reduction of immunosuppres-
sion in the context of CMV disease might be another con-
tributing factor.
As a consequence of the risks associated with post-
transplant CMV infection, CMV chemoprophylaxis and
preemptive treatment have become a standard of care over
the past decade (12). Typically, high-risk patients (donor
seropositive, patient seronegative) receive valganciclovir or
ganciclovir prophylaxis, whereas intermediate-risk patients
(recipient seropositive) are monitored by pp65 antigenemia
or nucleic acid testing and are treated preemptively. The
incidences of posttransplant CMV infection and disease have
as a consequence substantially decreased, and most CMV in-
fections occurring nowadays are asymptomatic replication
events. Whether CMV is still a risk factor for graft rejection
in the era of prophylactic or preemptive treatment has not
been systematically analyzed. Small studies in lung and kidney
transplant recipients treated prophylactically failed to find
an association between CMV replication and graft rejection
(13, 14). We therefore aimed to study the effect of CMV
replicationVasymptomatic and symptomaticVon the inci-
dence of rejection and graft failure in a large cohort of pa-
tients prospectively followed within the Swiss Transplant
Cohort Study (STCS).
RESULTS
Incidence of CMV Replication
and Acute Rejection
The 2-year cumulative incidence of CMV replication
amounted to 46%T6% in heart, 42%T2% in kidney, 41%T3%
in liver, and 31%T4% in lung allograft recipients (Figure S1A,
SDC, http://links.lww.com/TP/A976). The distribution be-
tween patients grouped by donor recipient serostatus was
similar in all organ groups, with overall CMV replication rates
of 3%T1% in Dj/Rj, 41%T3% in Dj/R+, 47%T3% in
D+/Rj, and 56%T2% in D+/R+ transplants, respectively.
Cytomegalovirus replication rates were not significantly in-
fluenced by the type of induction treatment (anti-lymphocyte
globulins vs. CD25 antibody) or by the type of maintenance
immunosuppression (cyclosporine vs. tacrolimus based). Of
the 487 first episodes of CMV replication, 52 (11%) were
symptomatic, whereas the remaining 435 (89%) were asymp-
tomatic. Of the asymptomatic episodes, 275 (63%) were
treated, whereas the remaining 160 (37%) were observed. The
number of patients developing a second, third, and fourth
episode of CMV replication were 142, 71, and 8, respectively,
with distributions between symptomatic and asymptomatic
replication similar to first episodes (data not shown).
Prophylaxis with valganciclovir was administered to
47% of the patients after transplantation with significant
differences between the types of organ transplanted (Table 1).
Most D+/Rj patients received CMV prophylaxis (79%),
whereas only half of the CMV seropositive recipients re-
ceived prophylactic treatment (50% and 49% for Dj/R+ and
D+/R+, respectively). The median duration of CMV pro-
phylactic treatment was 3.6 months (range, 0Y19 months).
At 4 years, the cumulative incidence of biopsy proven graft
rejection was 67%T5% in heart, 29%T2% in kidney, 41%T4%
in liver, and 34%T4% in lung transplant patients, respectively
(Figure S1B, SDC, http://links.lww.com/TP/A976).
CMV Replication and Rejection
Hazard ratios for the development of graft rejection
within 4 weeks after detection of CMV replication are shown
in Figure 1 for patients grouped by type of organ trans-
planted. A significant increase in the risk for graft rejection
was detected in all organs. Substantial differences were
noted between different organs, with the highest risk in lung
transplants and the lowest risk in kidney grafts (hazard ratio
(HR) for graft rejection after any type of CMV infection
event after heart transplantation, 2.60; 95% confidence in-
terval (CI), 1.34Y4.94; PG0.001; HR after kidney transplan-
tation, 1.58; 95% CI, 1.16Y2.16; P=0.02; HR after liver
transplantation, 2.21; 95% CI, 1.53Y3.17; PG0.001; HR after
lung transplantation, 5.83; 95% CI, 3.12Y10.9; PG0.001).
Interaction analysis revealed that the differences in hazard
ratios between organs were significant (P=0.003), whereas
when patients were grouped by transplanted organ, no sig-
nificant difference in the risk for graft rejection was evident
between patients with asymptomatic untreated, asymptom-
atic treated, and symptomatic CMV replication, respectively
(all interaction P values 90.1; Fig. 1).
Treatment of a rejection episode with escalation of im-
munosuppressive treatment might lead to CMV replication
and thereby lead to an overestimation of the effect of CMV
on graft rejection because patients with previous rejection
episodes are at an increased risk for further rejections. We
therefore next restricted the analysis to first episodes of CMV
replication, and this analysis showed a similar picture
(Figure S2, SDC, http://links.lww.com/TP/A976), albeit with
larger confidence intervals caused by the smaller number of
CMV replication events analyzed.
CMV Serology and Rejection
Having established that CMV replication increases the
relative risk of graft rejection, we were also interested in
quantifying whether CMV influences the absolute risk of
graft rejection. Although the risk of graft rejection was
clearly elevated after CMV replication, the time at risk
accounted for only 2% of total follow-up in this study (59
person-years of a total of 2,976 person-years of follow-up).
The number of rejection episodes occurring within 4 weeks
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after detection of CMV replication was 66 (9% of a total of
708 episodes).
As CMV replication was almost nonexistent in the Dj
and Rj populations, we compared total rates of graft re-
jection in this population compared with the pooled pop-
ulation of D+ or R+ transplants. This analysis revealed that
recipients of liver and lung, but not kidney or heart allo-
grafts, were at increased absolute risk of graft rejection if
donor or recipient were CMV seropositive at the time of
transplant (Fig. 2). In agreement with this, adjusted hazard
ratios for graft rejection between D+ and R+ patients and
Dj/Rj patients were 1.13 (95% CI, 0.68Y1.90; P=0.62) for
heart; 0.92 (95% CI, 0.72Y1.18; P=0.52) for kidney; 3.05
(95% CI, 1.49Y6.23; P=0.002) for liver; and 2.42 (95% CI,
1.19Y4.92; P=0.01) for lung allografts.
CMV Serology and Graft Loss
To address whether the increased risk of graft rejection
after CMV replication and in CMV D+ or R+ patients also
translated into more risk of graft loss, we compared the in-
cidence of graft loss in CMV Dj/Rj to D+ or R+ patients.
For all organs, graft loss occurred more frequently in
transplants involving a CMV seropositive donor or patients
(heart, 1% vs. 0%; kidney 6% vs. 2%; liver, 8% vs. 3%; lung,
11% vs. 0%; in CMV D+ or R+ vs. Dj/Rj, respectively;
TABLE 1. Patient characteristics
Organ transplanted Heart (n=97) Kidney (n=917) Liver (n=237) Lung (n=163)
Patient age at transplantation
Median (range) 50 (0Y70) 53 (0Y79) 54 (0Y71) 54 (9Y70)
Sex, n (%)
Men 72 (74) 599 (65) 153 (65) 79 (49)
Women 25 (26) 318 (35) 84 (35) 84 (52)
CMV serology, n (%)
Dj/Rj 21 (22) 190 (21) 36 (15) 36 (22)
Dj/R+ 20 (21) 198 (22) 63 (27) 35 (22)
D+/Rj 21 (22) 183 (20) 39 (17) 44 (27)
D+/R+ 32 (33) 333 (36) 91 (38) 47 (29)
Missing 3 (3) 13 (1) 8 (3) 1 (1)
No HLA-A/B/DR-mismatches, n (%)
0Y2 2 (2) 143 (16) 5 (2) 7 (4)
3Y4 27 (28) 399 (44) 160 (68) 48 (29)
5Y6 68 (70) 375 (41) 72 (30) 108 (66)
Antibody induction, n (%)
Anti-CD25 mAb 11 (11) 578 (63) 132 (60) 147 (90)
ATG 84 (87) 224 (24) 1 (0) 15 (9)
None 2 (2) 115 (13) 93 (39) 1 (1)
Maintenance immunosuppression, n (%)
Tacrolimus, mycophenolate, prednisone 35 (36) 626 (68) 140 (59) 58 (36)
Cyclosporine, mycophenolate, prednisone 55 (57) 274 (30) 57 (24) 102 (63)
Other 7 (7) 17 (2) 40 (17) 3 (2)
Valganciclovir prophylaxis, n (%)
No 48 (50) 546 (60) 192 (81) 38 (23)
Yes 48 (50) 371 (40) 45 (19) 125 (77)
CMV, cytomegalovirus; D, donor; R, recipient; HLA, human leukocyte antigen; mAb, monoclonal antibody; ATG, anti-lymphocyte globulins.
FIGURE 1. Forest plot of hazard ratios derived from time-
dependent Cox models analyzing the impact of CMV rep-
lication on the incidence of biopsy proven graft rejection
in recipients of heart (n=97), kidney (n=917), liver (n=237),
or lung (n=163) allografts. Cox models included induc-
tion and maintenance immunosuppression, number of HLA
mismatched between recipient and graft, and incidence of
previous rejection episodes as covariables. CMV, cyto-
megalovirus; HLA, human leukocyte antigen.
* 2014 Lippincott Williams & Wilkins Stern et al. 1015
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Fig. 3A). As prophylactic treatment with valganciclovir ef-
ficiently suppresses CMV replication during the time of pro-
phylactic administration (Fig. 3B), we wondered whether
valganciclovir treatment had any effect on graft survival.
Analysis of graft loss over time revealed that indeed, nonY
Dj/Rj patients receiving valganciclovir showed rates of graft
loss comparable to Dj/Rj patients in the first 6 months after
transplantation. In contrast, nonYDj/Rj patients not receiv-
ing CMV prophylaxis were at an increased risk of graft loss in
the first months after transplantation. After 2 years, however,
rates of graft loss were no longer lower in patients receiving
valganciclovir (CMV D+ or R+ with valganciclovir, 6%T1%;
without valganciclovir, 5%T1%; Dj/Rj, 2%T0%; Fig. 3C),
suggesting that valganciclovir delays rather than prevents
graft rejection.
DISCUSSION
Previous studies have correlated CMV replication and
disease after SOT with transplant outcome and have in their
majority shown that CMV replication is associated with
poor transplant outcome in graft rejection, graft survival,
and patient survival. These data, along with the availability
of valganciclovir, a highly efficient substance available for
oral treatment of CMV, has led to the widespread use of CMV
prophylaxis after SOT. Introduction of CMV prophylaxisV
along with monitoring and preemptive treatmentVhas re-
duced the incidence of symptomatic CMV disease and has
also significantly reduced the number of patients with asymp-
tomatic replication. Cytomegalovirus replication in patients
receiving prophylaxis is also typically delayed until prophy-
laxis is discontinued, a period when patients are potentially
at lower risk for graft rejection events. The significance of
CMV replication and disease in triggering graft rejection in
patients receiving transplants in the era of CMV prophylaxis
is therefore unclear.
We analyzed the correlation of CMV replication and
donor or recipient seroconstellation in a large cohort of
patients receiving solid organ allografts between 2008 and
2012 in any of the six transplant centers in Switzerland. We
found that, similar to earlier studies, CMV replication was
associated with more risk for graft rejection after heart, kidney,
liver, or lung transplantation. Although differences in the
relative risks were apparent between organ type (lowest in
kidney, highest in lung), we found no significant difference
between patients with asymptomatic and symptomatic CMV
infection. Further correlation between CMV serostatus and
transplant outcome showed more rate of graft rejection in
nonYlow-risk patients (i.e., nonYDj/Rj) receiving liver or
lung allografts, but not heart or kidney allografts. In contrast,
the incidence of graft loss was higher in nonYDj/Rj patients
compared with Dj/Rj controls in all organs analyzed. Time
to event analyses suggested that prophylactic treatment with
valganciclovir is able to delay rather than prevent graft loss
in nonYDj/Rj transplants. These results extend a recently
reported STCS analysis, which had analyzed the effect of
valganciclovir prophylaxis on graft failure-free survival (a
composite endpoint of graft failure and death) (11). In line
with this previous study, we confirmed in this cohort that
prophylactic treatment of CMV increases graft failure-free
survival (Figure S3, SDC, http://links.lww.com/TP/A976).
The rates of graft failure analyzed as a separate endpoint in
this study suggest that prophylactic valganciclovir treatment
may reduce the incidence of death without preceding graft
failure, and that this effect may be largely responsible for the
effect on graft failure-free survival.
The data shown here argue that despite prophylaxis,
CMV replication continues to be significantly associated
with graft rejection. This finding is corroborated by the
analysis of patients grouped by donor or recipient serology.
The data pose the question, whether prophylactic treatment
should be prolonged with the goal to prevent graft rejection
FIGURE 2. Cumulative incidence of graft rejection in patients grouped by transplanted organ and by donor recipient CMV
IgG serostatus at the time of transplantation. Transplants fromDj/Rj are comparedwith all other combinations (Dj/R+, D+/
Rj, D+/R+) combined (heart, n=97, P=0.69; kidney, n=917, P=0.14; liver, n=237, P=0.03; lung, n=163, P=0.03; all P values
by log-rank test). CMV, cytomegalovirus; IgG, immunoglobulin G; D, donor; R, recipient.
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and graft failure. Prolongation of valganciclovir adminis-
tration from 3 months to 12 months has recently been
shown to be feasible in a small study and led to reduced rates
of both CMV infection and acute rejection in lung trans-
plant recipients (15), although this could not be replicated
in a similar study (16). A significant reduction of CMV
disease was achieved by prolonging valganciclovir prophy-
laxis from 100 to 200 days after kidney transplantation, with
a nonsignificant reduction in rejection episodes occurring in
this study (17).
The data in the current cohort suggest that valgan-
ciclovir administration for approximately 4 months may be
too short to have an impact on long-term graft survival.
Whether longer-term administration of CMV prophylaxis
is indeed able to prevent rejections, or just further delays
rejection events, would need to be studied prospectively. A
potential limitation of this study is that monitoring for
CMV was only performed regularly in the first months after
transplantation. Late rejections may therefore have been pre-
ceded by undocumented CMV replication events. However,
most rejections occurred during the period in which CMV
replication was monitored. Despite this, the true risk of re-
jection associated with CMV replication events may be un-
derestimated because of incomplete monitoring throughout
the study period.
In conclusion, we show that in solid organ transplant
recipients receiving prophylactic or preemptive treatment of
CMV, infection with CMVVasymptomatic or symptomaticV
remains to be a risk factor for biopsy-proven acute graft re-
jection. In line with this, despite attempts to prevent CMV
replication or treat it early, CMV donor or recipient sero-
constellation remains associated with graft rejection in pa-
tients receiving liver or lung allografts, and with graft loss in all
organs analyzed.
MATERIALS AND METHODS
Study Design
The STCS is a prospective multicenter cohort study, enrolling patients
treated with SOT in six transplant centers in Switzerland since May 2008
(18). Data are collected on demographic parameters, transplant type, co-
morbidities, immunosuppressive treatment, antimicrobial drugs, rejection,
and infectious and noninfectious events at enrollment, at 6 months, and
every 12 months on standardized data forms. Specific data on CMV infec-
tion available in the STCS database include the use of antiviral drugs and
the type classified as asymptomatic replication, viral syndrome, and prob-
able and proven end-organ disease.
Patients
Of 2,119 solid organ transplants reported to SCTS within the timeframe
of the study, 1,414 patients undergoing first single SOT in Switzerland
between May 2008 and August 2012 were combined in this analysis
(Inselspital Bern, n=201; Centre Hospitalier Universitaire Vaudois, Lau-
sanne, n=228; Hoˆpitaux Universitaires de Gene`ve, n=158; Kantonsspital St.
Gallen, n=69; Universita¨tsspital Basel, n=222; Universita¨tsspital Zu¨rich,
n=536). We selected patients receiving a first single heart, kidney, liver, or
lung allograft. Seven hundred and nine patients receiving solid organ
transplants during the time frame of this study were excluded. Reasons for
exclusion were: transplantation of more than one organ (n=192), trans-
plantation of small bowel, pancreas, or pancreas islets (n=42), patients with
AB0 blood group barrier (n=20), patients with donor-specific antibodies
(n=52), nonYfirst transplants (n=42), or missing data (n=361). Induction
and maintenance immunosuppressive regimens are summarized in Table 1
along with demographic characteristics.
Cytomegalovirus serologic constellation was assessed by detecting antiY
CMV immunoglobulin G antibodies in donors and recipients at the time of
transplant. Screening for CMV replication by polymerase chain reaction
was performed at each transplant center every 1 to 2 weeks during the first
6 months after transplantation. Data on transplant characteristics and
transplant outcome including infectious complications were prospectively
collected using an electronic database. Written informed consent was
FIGURE 3. Rates of graft loss in Dj/Rj (white bars)
versus nonYDj/Rj (black bars) in recipients of heart (0%
vs. 1.4%; P=1.0), kidney (1.8% vs. 5.5%; P=0.02), liver
(2.8% vs. 7.6%; P=0.48), or lung (0% vs. 11%; P=0.08) al-
lografts (A). Cumulative incidence of CMV replication in
patients receiving (dashed line) or not (solid line) val-
ganciclovir (GCV) prophylaxis (B, all organs combined).
Cumulative incidence of graft loss in Dj/Rj allografts
(solid line, n=278), and in nonYDj/Rj allografts receiv-
ing (dotted line; n=555) or not (dashed line; n=560)
valganciclovir prophylaxis (P=0.16). D, donor; R, recipient;
CMV, cytomegalovirus.
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obtained from all study participants, and the study was institutional review
board approved at all centers.
Classification of CMV Replication
and Rejection Episodes
In general, only biopsy-proven rejection episodes were considered in this
study. Cardiac biopsies were classified according to the International Society
for Heart and Lung Transplantation guidelines (19), and any grade II or
higher histology was considered a rejection event. Renal biopsies were
classified according to the Banff classification (20), and rejection episodes of
grade IA and higher were classified as acute rejections. Pure humoral re-
jections defined as C4d deposition without any cellular involvement were
not considered in this study because the definition and the criteria to di-
agnose a pure acute humoral rejection differ from organ to organ. Liver
biopsies were categorized according to Banff Rejection Activity Index (21),
and scores of 3 or higher were considered acute rejection episodes. Lung
biopsies were classified according to the revised International Society for
Heart and Lung Transplantation guidelines (22), and grade II or higher
episodes were classified as acute rejection.
Cytomegalovirus replication was classified as asymptomatic (evidence of
CMV replication without symptoms) and symptomatic (viral syndrome or
tissue invasive disease). Asymptomatic replications were further classified into
those that resulted in antiYCMV treatment and into those observed only.
Statistical Analysis
Recipients of heart, kidney, liver, and lung allografts were analyzed sep-
arately. Cumulative incidences of CMV replication and of graft rejection
episodes were estimated using death and graft loss as competing risks. Cox
regression was used for multivariable analyses with graft rejection as an
endpoint, adjusting for type of induction and maintenance immunosup-
pression, number of human leukocyte antigen mismatches between donor
and graft andVin models that looked at more than one rejection episodeV
number of previous rejection events. Episodes of CMV replication were
coded as a time-dependent covariate. Because we did not have data on the
duration of CMV replication, we considered patients to be at risk for re-
jection for 4 weeks after first detection of CMV replication. In a subset of
analyses, multiple rejection events were considered, with the number of
previous rejections included in models as a stratification variable to ac-
count for the increased risk of rejections in patients with a history of pre-
vious rejections.
For the analysis of the effect of CMV prophylaxis on graft survival, all
patients experiencing early graft loss or death (occurring in the first 2 weeks
after transplantation) were excluded because follow-up in these patients
may have been too short to start a planned prophylactic treatment. Pro-
phylactic treatment was assumed if treatment with valganciclovir was ini-
tiated within 3 months after transplantation without a preceding CMV
replication event. Death without preceding graft failure was considered a
competing event in this analysis.
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